Cytokeratin and CDX-2 expression in Barrett's esophagus

References

• Koop H. Gastroesophageal reflux disease and Barrett's esophagus. Endoscopy 2004; 36: 103–9
   PubMedGoogle Scholar
• Triadafilopoulos G. Management of Barrett's esophagus with and without dysplasia. Scand. J. Gastroenterol. Suppl. 2003; 237: 40–6
   Google Scholar
• Haag S, Holtmann G. Reflux disease and Barrett's esophagus. Endoscopy 2003; 35: 112–7
   PubMedGoogle Scholar
• Jankowski JA, Harrison RF, Perry I, Balkwill F, Tselepis C. Barrett's metaplasia. Lancet 2000; 356: 2079–85
   PubMed Web of Science ®Google Scholar
• Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus?. Gastroenterology 2000; 119: 333–8
   PubMed Web of Science ®Google Scholar
• Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989; 96: 1249–56
   PubMed Web of Science ®Google Scholar
• Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997; 92: 212–5
   PubMed Web of Science ®Google Scholar
• Devesa SS, Blot WJ, Fraumeni JF, Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049–53
   PubMed Web of Science ®Google Scholar
• Prach AT, MacDonald TA, Hopwood DA, Johnston DA. Increasing incidence of Barrett's oesophagus: education, enthusiasm, or epidemiology?. Lancet 1997; 350: 933
   PubMed Web of Science ®Google Scholar
• Bytzer P, Christensen PB, Damkier P, Vinding K, Seersholm N. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study. Am J Gastroenterol 1999; 94: 86–91
   PubMed Web of Science ®Google Scholar
• Ford AC, Forman D, Reynolds PD, Cooper BT, Moayyedi P. Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus. Am J Epidemiol 2005; 162: 454–60
   PubMed Web of Science ®Google Scholar
• Wong A, Fitzgerald RC. Epidemiologic risk factors for Barrett's esophagus and associated adenocarcinoma. Clin Gastroenterol Hepatol 2005; 3: 1–10
   PubMed Web of Science ®Google Scholar
• Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 2002; 123: 461–7
   PubMed Web of Science ®Google Scholar
• Hirota WK, Loughney TM, Lazas DJ, Maydonovitch CL, Rholl V, Wong RK. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology 1999; 116: 277–85
   PubMed Web of Science ®Google Scholar
• Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825–31
   PubMed Web of Science ®Google Scholar
• Reid BJ, Blount PL, Rabinovitch PS. Biomarkers in Barrett's esophagus. Gastrointest Endosc Clin N Am 2003; 13: 369–97
   PubMedGoogle Scholar
• Krishnadath KK, Tilanus HW, van Blankenstein M, Hop WC, Teijgeman R, Mulder AH, et al. Accumulation of genetic abnormalities during neoplastic progression in Barrett's esophagus. Cancer Res 1995; 55: 1971–6
   PubMedGoogle Scholar
• El-Zimaity HM, Graham DY. Cytokeratin subsets for distinguishing Barrett's esophagus from intestinal metaplasia in the cardia using endoscopic biopsy specimens. Am J Gastroenterol 2001; 96: 1378–82
   PubMedGoogle Scholar
• Ormsby AH, Goldblum JR, Rice TW, Richter JE, Falk GW, Vaezi MF, et al. Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach. Hum Pathol 1999; 30: 288–94
   PubMedGoogle Scholar
• Moll R. Cytokeratins in the histological diagnosis of malignant tumors. Int J Biol Markers 1994; 9: 63–9
   PubMedGoogle Scholar
• Chu PG, Jiang Z, Weiss LM. Hepatocyte antigen as a marker of intestinal metaplasia. Am J Surg Pathol 2003; 27: 952–9
   PubMed Web of Science ®Google Scholar
• Phillips RW, Frierson HF, Jr, Moskaluk CA. CDX2 as a marker of epithelial intestinal differentiation in the esophagus. Am J Surg Pathol 2003; 27: 1442–7
   PubMed Web of Science ®Google Scholar
• Suh E, Chen L, Taylor J, Traber PG. A homeodomain protein related to caudal regulates intestine-specific gene transcription. Mol Cell Biol 1994; 14: 7340–51
   PubMed Web of Science ®Google Scholar
• Freund JN, Domon-Dell C, Kedinger M, Duluc I. The Cdx-1 and Cdx-2 homeobox genes in the intestine. Biochem Cell Biol 1998; 76: 957–69
   PubMed Web of Science ®Google Scholar
• James R, Erler T, Kazenwadel J. Structure of the murine homeobox gene cdx-2. Expression in embryonic and adult intestinal epithelium. J Biol Chem 1994; 269: 15229–37
   PubMed Web of Science ®Google Scholar
• Suh E, Traber PG. An intestine-specific homeobox gene regulates proliferation and differentiation. Mol Cell Biol 1996; 16: 619–25
   PubMed Web of Science ®Google Scholar
• Mesquita P, Jonckheere N, Almeida R, Ducourouble MP, Serpa J, Silva E, et al. Human MUC2 mucin gene is transcriptionally regulated by Cdx homeodomain proteins in gastrointestinal carcinoma cell lines. J Biol Chem 2003; 278: 51549–56
   PubMedGoogle Scholar
• Grotzinger C, Kneifel J, Patschan D, Schnoy N, Anagnostopoulos I, Faiss S, et al. LI-cadherin: a marker of gastric metaplasia and neoplasia. Gut 2001; 49: 73–81
   PubMed Web of Science ®Google Scholar
• Boudreau F, Rings EH, van Wering HM, Kim RK, Swain GP, Krasinski SD, et al. Hepatocyte nuclear factor-1 alpha, GATA-4, and caudal related homeodomain protein Cdx2 interact functionally to modulate intestinal gene transcription. Implication for the developmental regulation of the sucrase-isomaltase gene. J Biol Chem 2002; 277: 31909–17
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Bai YQ, Yuasa Y. Homeodomain protein CDX2 regulates goblet-specific MUC2 gene expression. Biochem Biophys Res Commun 2003; 300: 813–8
   PubMed Web of Science ®Google Scholar
• Traber PG, Silberg DG. Intestine-specific gene transcription. Annu Rev Physiol 1996; 58: 275–97
   PubMedGoogle Scholar
• Mitchelmore C, Troelsen JT, Spodsberg N, Sjostrom H, Noren O. Interaction between the homeodomain proteins Cdx2 and HNF1alpha mediates expression of the lactase-phlorizin hydrolase gene. Biochem J 2000; 346: 529–35
   PubMedGoogle Scholar
• Fang R, Santiago NA, Olds LC, Sibley E. The homeodomain protein Cdx2 regulates lactase gene promoter activity during enterocyte differentiation. Gastroenterology 2000; 118: 115–27
   PubMed Web of Science ®Google Scholar
• Krasinski SD, Van Wering HM, Tannemaat MR, Grand RJ. Differential activation of intestinal gene promoters: functional interactions between GATA-5 and HNF-1 alpha. Am J Physiol Gastrointest Liver Physiol 2001; 281: G69–84
   PubMed Web of Science ®Google Scholar
• Taylor JK, Boll W, Levy T, Suh E, Siang S, Mantei N, et al. Comparison of intestinal phospholipase A/lysophospholipase and sucrase-isomaltase genes suggest a common structure for enterocyte-specific promoters. DNA Cell Biol 1997; 16: 1419–28
   PubMedGoogle Scholar
• Sakaguchi T, Gu X, Golden HM, Suh E, Rhoads DB, Reinecker HC. Cloning of the human claudin-2 5′-flanking region revealed a TATA-less promoter with conserved binding sites in mouse and human for caudal-related homeodomain proteins and hepatocyte nuclear factor-1 alpha. J Biol Chem 2002; 277: 21361–70
   PubMed Web of Science ®Google Scholar
• Bai YQ, Yamamoto H, Akiyama Y, Tanaka H, Takizawa T, Koike M, et al. Ectopic expression of homeodomain protein CDX2 in intestinal metaplasia and carcinomas of the stomach. Cancer Lett 2002; 176: 47–55
   PubMed Web of Science ®Google Scholar
• Eda A, Osawa H, Satoh K, Yanaka I, Kihira K, Ishino Y, et al. Aberrant expression of CDX2 in Barrett's epithelium and inflammatory esophageal mucosa. J Gastroenterol 2003; 38: 14–22
   PubMed Web of Science ®Google Scholar
• van Baal JW, Milano F, Rygiel AM, Bergman JJ, Rosmolen WD, van Deventer SJ, et al. A comparative analysis by SAGE of gene expression profiles of Barrett's esophagus, normal squamous esophagus, and gastric cardia. Gastroenterology 2005; 129: 1274–81
   PubMed Web of Science ®Google Scholar
• Mohammed IA, Streutker CJ, Riddell RH. Utilization of cytokeratins 7 and 20 does not differentiate between Barrett's esophagus and gastric cardiac intestinal metaplasia. Mod Pathol 2002; 15: 611–6
   PubMedGoogle Scholar
• Glickman JN, Wang H, Das KM, Goyal RK, Spechler SJ, Antonioli D, et al. Phenotype of Barrett's esophagus and intestinal metaplasia of the distal esophagus and gastroesophageal junction: an immunohistochemical study of cytokeratins 7 and 20, Das-1 and 45 MI. Am J Surg Pathol 2001; 25: 87–94
   PubMed Web of Science ®Google Scholar
• Moons LM, Bax DA, Kuipers EJ, Van Dekken H, Haringsma J, Van Vliet AH, et al. The homeodomain protein CDX2 is an early marker of Barrett's oesophagus. J Clin Pathol 2004; 57: 1063–8
   PubMed Web of Science ®Google Scholar
• Groisman GM, Amar M, Meir A. Expression of the intestinal marker Cdx2 in the columnar-lined esophagus with and without intestinal (Barrett's) metaplasia. Mod Pathol 2004; 17: 1282–8
   PubMed Web of Science ®Google Scholar
• Rugge, M, Ingravallo, G, Farinati, F, Russo, VM, Zaninotto, G, Alvisi, V. Re: CDX2 homeotic gene expression in gastric noninvasive neoplasia. Am J Surg Pathol 2004;28:834–5; 835 [author reply].
   PubMedGoogle Scholar
• Lord RV, Brabender J, Wickramasinghe K, DeMeester SR, Holscher A, Schneider PM, et al. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma. Surgery 2005; 138: 924–31
   PubMed Web of Science ®Google Scholar
• Steininger H, Pfofe DA, Muller H, Haag-Sunjic G, Fratianu V. Expression of CDX2 and MUC2 in Barrett's mucosa. Pathol Res Pract 2005; 201: 573–7
   PubMed Web of Science ®Google Scholar
• Silberg DG, Sullivan J, Kang E, Swain GP, Moffett J, Sund NJ, et al. Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. Gastroenterology 2002; 122: 689–96
   PubMed Web of Science ®Google Scholar